Table 4 Patients characteristics in the conversion group
Age (years) | Sex | Primary | T category | Node positive | Tumor size (mm) | Tumor number | Regimen | No. of lines | No. of cycles | Clinical response | Resection | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 65 | M | Colon | 3 | + | 80 | ≥5 | Cmab + FOLFIRI | 1 | 3 | PR | 1 |
2 | 57 | M | Rectum | 3 | + | 50 | ≥5 | Bmab + FOLFOX6 | 1 | 17 | PR | 0 |
3 | 52 | F | Colon | 4 | + | 30 | ≥5 | Cmab + FOLFIRI | 1 | 3 | PR | 1 |
4 | 51 | M | Colon | 3 | − | 20 | 2–4 | Bmab + FOLFOX6 | 1 | 18 | PR | 0 |
5 | 60 | M | Rectum | 4 | + | 50 | ≥5 | Cmab + FOLFOX6 | 1 | 7 | PR | 1 |
6 | 67 | M | Colon | 4 | − | 30 | ≥5 | Cmab + FOLFOX6 | 1 | 8 | PR | 1 |
7 | 78 | M | Colon | 3 | − | 20 | ≥5 | Cmab + FOLFOX6 | 1 | 15 | PR | 1 |
8 | 32 | F | Colon | 3 | + | 100 | ≥5 | Bmab + FOLFOX6 | 1 | 8 | SD | 1 |
9 | 80 | F | Colon | 3 | − | 32 | ≥5 | Bmab + FOLFOX6 | 1 | 4 | PR | 0 |
10 | 44 | F | Colon | 3 | + | 100 | ≥5 | Cmab + FOLFOX6 | 1 | 3 | SD | 0 |
11 | 33 | F | Colon | 3 | + | 24 | ≥5 | Bmab + FOLFOX6 | 1 | 2 | PR | 0 |
12 | 56 | F | Colon | 3 | − | 80 | 2–4 | Cmab + FOLFOX6 | 1 | 3 | PR | 0 |
13 | 58 | M | Colon | 3 | + | 40 | ≥5 | Cmab + FOLFIRI/Bmab + Xelox | 2 | 18 | PR | 1 |
14 | 55 | F | Colon | 4 | − | 55 | ≥5 | Cmab + FOLFOX6 | 1 | 3 | PR | 0 |
15 | 58 | F | Rectum | 3 | + | 40 | 1 | Cmab + FOLFOX6 | 1 | 3 | SD | 0 |
16 | 65 | M | Rectum | 3 | − | 23 | ≥5 | Pmab + FOLFOX6 | 1 | 3 | PR | 0 |